Download MendeleySolution-phase parallel synthesis of Hsp90 inhibitors
Cho-Schultz, S., Patten, M.J., Huang, B., Elleraas, J., Gajiwala, K.S., Hickey, M.J., Wang, J., Mehta, P.P., Kang, P., Gehring, M.R., Kung, P.P., Sutton, S.C.(null) J Comb Chem 11: 860-874
- PubMed: 19583220
- DOI: https://doi.org/10.1021/cc900056d
- Primary Citation of Related Structures:
3HEK - PubMed Abstract:
As part of an oncology chemistry program directed toward discovery of orally bioavailable inhibitors of the 90 kDa heat shock protein (Hsp90), several solution-phase libraries were designed and prepared. A 2 x 89 library of racemic resorcinol amides was prepared affording 131 purified compounds. After evaluation in a binding assay, followed by an AKT-Luminex cellular assay, three potent analogs had functional activity between 0.1 and 0.3 microM. Resolution by preparative chiral SFC chromatography led to (+)-15, (+)-16, and (+)-17 having functional IC(50) = 27, 43, and 190 nM, respectively. (+)-15 exhibited high clearance in human hepatocytes driven primarily by glucuronidation as confirmed by metabolite identification. A second 8 x 14 exploratory library was designed to investigate heterocyclic replacements of the resorcinol ring. The second library highlights the use of the (-)-sparteine-mediated enantioselective Pd-catalyzed alpha-arylation of N-Boc-pyrrolidine to prepare chiral 2-arylpyrrolidines in parallel.
Organizational Affiliation:
Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, USA.
